Chase Pharmaceuticals

Chase Pharmaceuticals (CPC) has been pioneering advancements in neuropsychiatric treatment since its establishment in 2007. The company's focus on identifying and developing promising treatments for central nervous system (CNS) diseases aligns with the critical medical needs of neuropsychiatric patients. CPC's operations involve selecting, licensing-in, advancing, and licensing-out drug candidates for commercial partners, with a strong emphasis on effective selection, deep developmental knowledge, and efficient regulatory strategies. The significant unmet need in neuropsychiatry, particularly within Alzheimer's disease (AD) and related neurodegenerative disorders, serves as CPC's primary target. AD, affecting approximately 37 million people globally, poses a substantial burden estimated at over $600 billion annually. Despite AD medication sales reaching $4.7 billion, current treatments offer only marginal symptom improvement, with poor tolerability and high dropout rates. In 2016, CPC secured a $3.50M Series B investment, showcasing investor confidence in its potential to address critical unmet needs in neuropsychiatric treatment. The company's innovative approach of inventing and patenting a unique combination of existing pharmaceuticals for the symptomatic treatment of AD demonstrates commitment to addressing the global burden of CNS diseases. Chase Pharmaceuticals' efforts present a compelling opportunity in the biotechnology and healthcare industries, aiming for a brighter future in neuropsychiatric treatment.